Dusan Stefoski to Multiple Sclerosis
This is a "connection" page, showing publications Dusan Stefoski has written about Multiple Sclerosis.
Connection Strength
1.753
-
Treatment of natalizumab-associated PML with filgrastim. Ann Clin Transl Neurol. 2019 May; 6(5):923-931.
Score: 0.612
-
A plain language summary on assessing the long-term effectiveness of cladribine tablets in people living with relapsing multiple sclerosis: The CLASSIC-MS study. Neurodegener Dis Manag. 2023 Oct; 13(5):261-268.
Score: 0.206
-
Cyclophosphamide for severe acute forms of central nervous system inflammatory disorders. J Neurol Sci. 2023 08 15; 451:120693.
Score: 0.204
-
Long-term follow-up of patients with relapsing multiple sclerosis from the CLARITY/CLARITY Extension cohort of CLASSIC-MS: An ambispective study. Mult Scler. 2023 05; 29(6):719-730.
Score: 0.202
-
Long-term safety and efficacy of daclizumab beta in relapsing-remitting multiple sclerosis: 6-year results from the SELECTED open-label extension study. J Neurol. 2020 Oct; 267(10):2851-2864.
Score: 0.165
-
Is cervical decompression beneficial in patients with coexistent cervical stenosis and multiple sclerosis? J Clin Neurosci. 2014 Dec; 21(12):2189-93.
Score: 0.111
-
Indolent course of progressive multifocal leukoencephalopathy during natalizumab treatment in MS. Neurology. 2011 Sep 06; 77(10):1020; author reply 1020.
Score: 0.090
-
Freedom from disease activity in multiple sclerosis. Neurology. 2010 Apr 27; 74 Suppl 3:S3-7.
Score: 0.082
-
Hematopoietic stem cell transplantation for multiple sclerosis. Arch Neurol. 2005 Jun; 62(6):860-4.
Score: 0.059
-
IRF-1 signaling in central nervous system glial cells regulates inflammatory demyelination. J Neuroimmunol. 2011 Apr; 233(1-2):147-59.
Score: 0.022